Evidence map›Paper›PMID 32902720›Full record

ArticleCytotechnology2020

MiR-548c-3p inhibits the proliferation, migration and invasion of human breast cancer cell by targeting E2F3.

Pei-Yi Tan, Liu-Jing Wen, Hua-Nan Li, Shi-Wei Chai

Open access · bronzeAbstract read
In one paragraph

Article in Cytotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pan-inhibition of the three HCancer cell international · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. siRNA and targeted delivery systems in breast cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Pei-Yi TanFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Liu-Jing WenNational Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China.
Hua-Nan LiFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Shi-Wei ChaiFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China. chaishiwei791109@sina.com.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · CNTianjin Medical University Cancer Institute and Hospital · CN

Funding

Tuo Xin Project. Research Funding of First Teaching Hospital of Tianjin University of Traditional Chinese Medicine 201902
6 · The paper itself

Abstract

MiR-548 has been reported to be involved in a variety of tumor processes, but its function in breast cancer remains unclear. In this study, we found that miR-548 was low expressed in breast cancer tissues and cells compared with normal control. We then examined whether up-regulation of miR-548 could improve the progression of breast cancer. Our results indicate that up-regulation of miR-548 significantly inhibits cell proliferation, migration andinvasion, and induces apoptosis in breast cancer cells. Further studies showed that miR-548 could specifically inhibit E2F3 expression. Moreover, rescue test showed that up-regulation of E2F2 could reverse the effect of miR-548 on proliferation, migration, invasion and apoptosis of breast cancer cells. In general, miR-548 could improve the progression of breast cancer. By targeting E2F2, which may make a potential target for the treatment of breast cancer.

Indexed as

Breast cancerE2F3miR-548c-3pProliferation

Identifiers

PMID32902720
PMCPMC7547945
OpenAlexW3085587511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.